Fluicell positioned to accelerate growth

In this edition of the Fluicell CEO Newsletter, Victoire Viannay talks about the advances that Fluicell has made on the bioprinting market, where Biopixlar increasingly is being positioned as a leading technology that is bringing the field to the next level. Victoire also discusses how the recently completed directed share issue and the advancements made within R&D, fuel the Fluicell’s regenerative medicine agenda and lays the foundation for further growth.

Read all about this and more in the new issue of the Fluicell CEO Newsletter, which you can access here.


This newsletter is an edited version of the CEO words that was published as part of the 2021 Q3 report.